VigiQuest

The UK dietary supplements market was valued at approximately USD 4.79 billion in 2024 and is projected to reach nearly USD 9.65 billion by 2033, growing at around 8.1% annually. A sophisticated, health-conscious consumer base, with the most positive attitude toward supplements in Europe, makes the UK genuinely compelling for Canadian NHP manufacturers looking beyond North America. But Brexit fundamentally restructured how natural health products are regulated in Great Britain (England,...

Introduction The Japanese market for natural health products (NHPs) represents a significant opportunity for Canadian manufacturers, but it is also one of the most regulated globally. Japan’s pharmacovigilance framework is rigorous, reflecting the country’s high standards for drug safety, quality, and efficacy. For Canadian NHP manufacturers seeking to export to Japan, understanding the regulatory framework, key agencies involved, and specific pharmacovigilance requirements is essential to...

On May 22, 2026, Health Canada rolled out an extensive, synchronized update to its foundational Good Pharmacovigilance Practices (GVP) framework. Replacing standard documentation that hadn't seen a major refresh since 2013, these updates refine how drug safety data is captured, how inspections are carried out, and how GVP-related risks are classified. For pharmaceutical and biologic manufacturers, the changes clarify expectations. But for Natural Health Product (NHP) manufacturers and Market...